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PURPOSE. Melanopsin expressing intrinsically photosensitive retinal ganglion cells (ipRGC)
input to multiple brain regions including those for pupil control, circadian rhythms, sleep and
mood regulation. Here we measured ipRGC function and its relationship to sleep quality and
depression in patients with advanced AMD.
METHODS. The melanopsin-mediated post-illumination pupil response (PIPR) was measured in
53 patients with advanced AMD (age 78.8 6 8.8 years) and in 20 healthy controls (age 72.5 6
3.3 years). Sleep quality and efficiency was assessed using the Pittsburgh Sleep Quality Index
(PSQI). Risk of depression was determined using the Center for Epidemiologic Studies
Depression questionnaire.
RESULTS. The group with AMD showed significantly reduced pupil constrictions (P ¼ 0.039);
PIPR amplitudes (P ¼ 0.003); global sleep scores (P ¼ 0.01); and higher levels of depression
(P < 0.001) than the control group. There was a significant correlation between the PIPR
amplitude and global sleep score in the AMD group (P ¼ 0.01). The amplitude of PIPR
significantly correlated with sleep efficiency (P ¼ 0.008; regression, P ¼ 0.01, R2 ¼ 0.13), but
not sleep quality (P ¼ 0.23) in the AMD group. There was no correlation between PIPR and
depression scores.
CONCLUSIONS. Intrinsically photosensitive RGC dysfunction in advanced AMD contributes to
the observed reduction in sleep efficiency. The correlation between the melanopsin-mediated
PIPR and sleep may indicate reduced photic input to the suprachiasmatic nucleus and
ventrolateral preoptic area due to ipRGC dysfunction in AMD.
Keywords: intrinsically photosensitive retinal ganglion cells (ipRGCs), pupil light reflex, post-
illumination pupil response, sleep, depression
Melanopsin-expressing intrinsically photosensitive retinalganglion cells (ipRGCs) are dysfunctional in various
retinal and optic nerve diseases,1–4 including AMD.5,6 Non-
image forming functions of these cells include signaling
irradiance information for synchronizing the circadian body
clock to the solar day,7 thus mediating photoentrainment
through projections to the suprachiasmatic nucleus (SCN)8,9
and sleep induction through activation of the ventrolateral
preoptic area.10,11 Intrinsically photosensitive RGC dysfunction
could therefore alter sleep-wake cycles and affect sleep quality.
Intrinsically photosensitive RGCs also signal to the olivary
pretectal nucleus (OPN) for mediation of the pupil light reflex
(PLR)12,13 and in particular the post-illumination pupil response
(PIPR),12–15 which is an emerging method for the direct
assessment of ipRGC function in healthy and diseased eyes and
in persons with chronobiological disorders.4–6,12–14,16–18 Two
recent studies observed that sleep duration was altered in
advanced AMD patients; sleep duration decreased in wet AMD
and increased in dry AMD,19,20 but the effect of aberrant ipRGC
signaling in AMD5,6 as a contributing factor was not evaluated.
Supporting evidence for an association between ipRGC
dysfunction and sleep disorders is provided in primary open
angle glaucoma patients,1,3 where there is also decreased sleep
quality.16,17
Intrinsically photosensitive RGCs project to brain areas
implicated in mood regulation21 and patients with seasonal
affective disorder (SAD) have a dysfunctional melanopsin-
mediated PIPR,22 indicative of a role of aberrant ipRGC
signaling in the presence of SAD. In mouse models, depres-
sion-related behavior in wild-type mice is observed in response
to an altered light and dark cycle but not in ipRGC-deficient
mice,21 demonstrating the ability of light signaling via ipRGCs
to influence mood. Given that the melanopsin-mediated PIPR is
affected in early and late AMD,5,6 and the prevalence of
depression in AMD patients is as high as 39%,23–26 with its
origin likely to be multifactorial,27 we determined the role that
ipRGC dysfunction in AMD patients has in depression. Based on
this evidence, the study aim is to investigate whether ipRGC
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dysfunction in AMD is correlated with sleep and mood
disorders in patients with advanced stages of this condition.
Here we measure melanopsin function using the post-
illumination pupil response, and sleep and mood with
validated questionnaires to assess nonvisual behavioral disor-
ders in the AMD patients.
METHODS
Participants
Seventy three participants (41 female, 32 male) were recruited
from the Queensland Eye Institute (QEI), Queensland Univer-
sity of Technology (QUT) eye clinic, and local optometry
practices. Table 1 provides a summary of the participants’
clinical characteristics. Forty six of these participants had
advanced neovascular AMD (choroidal neovascularization
[CNV]; AREDS grade 4)28 and were under treatment with
antivascular endothelial growth factor (Lucentis; Genentech,
San Francisco, CA, USA, or Eylea; Regeneron Pharmaceuticals,
Inc., Tarrytown, NY, USA). Seven participants had advanced
geographic atrophy (GA; AREDS grade 4) and 20 participants
served as healthy controls. The age range of the healthy
controls is lower than that of the AMD patients (Table 1),
however, this age difference was not statistically significant. All
participants underwent an ophthalmic examination that
included visual acuity, ophthalmoscopy, intraocular pressure
measurement and optical coherence topography (OCT, Cirrus
HD-OCT; Carl Zeiss Meditec, Inc., Dublin, CA, USA). Although
36 participants had intraocular lens (IOL) implants, all
participants had normal iris musculature postsurgery and
cataract removal surgery does not adversely affect circadian
rhythm or sleep,29 with no difference in blue light transmission
between blue-blocking and neutral IOLs.29,30 Those partici-
pants without IOLs (AMD, n ¼ 21; control, n ¼ 16) had
crystalline lens opacities less than grade 2 (LOCS III),31 thus
limiting the effect of blue light attenuation by the aging lens.32
Clinical trials show that an average of 5.6 anti-VEGF injections
is administered over 12 months in patients suffering from
neovascular AMD.33–35 This is in accordance with the
treatment frequency in our cohort of 5.8 injections per year;
therefore, the number of injections administered was grouped
in increments of six for comparison of the treatment effect
within a 12-month period (Table 1). Five out of 53 AMD
patients were taking antidepressant medication (Zoloft; Pfizer,
Inc., New York, NY, USA; Lumin; Alphapharm Pty Limited,
Millers Point NSW, Australia; or Lexam; Aspen Pharma Pty Ltd,
St. Leonards NSW, Australia) that could affect the pupil
response; this was considered in the statistical analysis. There
was no history of ocular disease or medication affecting the
pupil in the control participants. The patients with AMD had
no ocular disease other than AMD. Written informed consent
was obtained from all participants and the study was
conducted in accordance with the requirements of the
Queensland University of Technology Human Research Ethics
Committee and the tenets of the Declaration of Helsinki.
Assessment of Sleep and Depression
Sleep was assessed using the Pittsburgh Sleep Quality Index
(PSQI) questionnaire,36 a self-assessed screening tool that has
been used to determine sleep disturbances in glaucoma37,38
and to determine sleep quality prior to measurement of the
circadian response of ipRGCs.8 The questionnaire is primarily
designed to measure sleep based on a global score. Presence
and risk of depression was determined using the Center for
Epidemiologic Studies Depression Scale (CES-D),39 a self-report
test designed to measure symptoms associated with depres-
sion. The 20-item CES-D questionnaire comprises six scales
reflecting the major facets of depression: depressed mood,
feelings of guilt and worthlessness, feelings of helplessness and
hopelessness, psychomotor retardation, loss of appetite, and
sleep disturbance. These symptoms have been used in
previously validated scales and the CES-D has high test-retest
reliability and internal consistency.39 The Seasonal Pattern
Assessment Questionnaire (SPAQ)40 was used to screen for the
presence of seasonal affective disorder (SAD) and provided
insight into factors such as social activity, weight, appetite, and
energy that may influence mood. While the SPAQ has high
specificity, it has low sensitivity and was therefore used for
screening rather than as a diagnostic instrument.41
Pupillometry
To assess ipRGC function, we measured the melanopsin-
mediated PIPR using customized paradigms developed in our
laboratory,1,5,6,42,43 with high irradiance stimuli designed for
use with a pupillographer (RAPDx; Konan Medical USA, Inc.,
Irvine, CA, USA). Intrinsically photosensitive RGCs produce a
sustained pupil constriction after offset of short wavelength
light known as the PIPR,12–14 which is absent with presenta-
tion of long-wavelength stimuli that have low melanopsin
excitation. Intrinsically photosensitive RGCs also receive
extrinsic signals from rods and cones,44–46 which can be
measured by the initial pupil constriction amplitude.47
Monocular red and blue light stimuli were presented in
Newtonian view on a liquid crystal display with a 40-Hz frame
rate, with a central physical barrier creating two optical
channels for recording binocular pupil responses under
infrared illumination. The screen was viewed at infinity
through a pair of 50-mm objective lenses to produce a 258
field of view in each eye. Monochromatic stimuli included a 10-
second pulse of blue light (short wavelength, kmax ¼ 448 nm,
corneal irradiance: 14.5 log quanta.cm2.s1, luminance: 1.3
log cd.m2) and red light (long wavelength, kmax ¼ 604 nm,
corneal irradiance: 14.4 log quanta.cm2.s1, luminance: 1.0
log cd.m2). The spectral outputs of the LED stimuli were
measured with a spectroradiometer (StellarNet, Tampa, FL,
USA) and irradiance and luminance was measured with a
radiometer (ILT1700 Research Radiometer; International Light
Technologies, Peabody, MA, USA). A target (green cross) was
TABLE 1. Summary of AMD Patient and Control Participant Distribu-
tion Based on Their Clinical Characteristics
Characteristics CNV Group GA Group Control Group
Participants, n 46 7 20
Age, y 78.4 6 8.7 80.7 6 9.7 72.5 6 3.3
Sex, M/F 16/30 4/3 12/8
IOL, n 28 4 4
VA (Snellen), n
6/6–6/12 22 0 20
6/15–6/36 17 4 0
6/48–CF 7 3 0
Number of injections, n
0–6 11 – –
7–12 6 – –
13–18 6 – –
19–24 8 – –
25–30 5 – –
31–36 6 – –
37–50 4 – –
CF, counting fingers; VA, visual acuity.
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used for patient fixation. A display screen mounted on the side
of the pupillographer (Konan Medical USA, Inc.) allowed the
examiner to monitor patient fixation during testing.
Procedure
Where AMD was present in both eyes, the worse eye was
dilated with 1% tropicamide (Alcon Laboratories, NSW,
Australia), and the preferential eye was dilated in healthy
controls. The consensual PLR was measured. Participants were
adapted to the dim room illumination (<1 lux) for 10 minutes
prior to testing. The pupil testing started with an additional 10
seconds dark adaptation before recording. Baseline pupil
diameter was then measured during 5 seconds of fixation
prior to onset of the 10-second stimulus and the post-stimulus
response was recorded for 40 seconds. This resulted in a 55-
second interstimulus interval between the long and short
wavelengths stimulus. Questionnaires were administered while
the patients’ eye was dilating. All testing occurred between 8
AM and 4 PM to minimize the effect of circadian variation on
the PIPR amplitude.8,48
Data Analysis
The Pittsburgh Sleep Quality Index comprises seven compo-
nents that are each scored on a Likert scale from 0 to 3 and
then summed to provide a global score, with higher scores
indicating poorer sleep quality.36 While global scores provide
an indication of overall sleep quality, factor analysis has since
shown that a multiple factor model is statistically favored over
a global score49,50; therefore, we scored and analyzed the PSQI
using sleep quality and sleep efficiency components.50 Sleep
quality included scores from the subjective sleep quality, sleep
latency, and sleep disturbance components, while sleep
efficiency included scores from sleep duration and calculated
sleep efficiency components (time in bed versus time asleep).
Sleep factor scores were calculated by multiplying the
component score by the factor loading given by Magee et
al.50 and summing them.
The Center for Epidemiologic Studies Depression question-
naire is also scored on a Likert scale from 0 to 3, with higher
scores indicating more depression symptoms, weighted by
frequency of occurrence during the past week.39 A cutoff score
of 16 helps in identifying people at risk for clinical depression.
Using continuous scoring criteria as described by Radloff,39
patients were identified as having no clinically significant
depression symptoms, subthreshold depression symptoms,
possible or probable major depressive symptoms, or having
met major depressive episode criteria. Where depressive
symptoms were a concern, the treating ophthalmologist for
the AMD patients was informed, and control participants were
advised to see a general practitioner. The Seasonal Pattern
Assessment Questionnaire measures seasonal variations in six
items (mood, appetite, weight, sleep, energy, and socializing)
by scoring each item on a 5-point scale ranging from 0 (no
change) to 4 (marked change). The global score (range 0–24)
was calculated by adding the individual item scores and a score
‡11 identified the presence of SAD.51
Pupil analysis included identification and extraction of blink
artefacts during analysis of pupil recordings by a customized
software algorithm with linear interpolation.43 The data were
fitted with linear and exponential models6,8 and analyzed
according to our established protocols.43 To control for
individual differences in resting pupil diameter, all data are
reported as a percentage of the resting baseline pupil diameter
(average pupil diameter during a 5-second prestimulus
period)42,43; a larger percentage value indicates smaller
constriction amplitude. The PIPR was quantified at 6 seconds
after light stimulus offset.52 Initial pupil constriction was
defined as the minimum pupil diameter within 3 seconds after
stimulus onset.53,54 The short wavelength stimulus with high
melanopsin excitation (609.8 a-opic lux) served to measure the
intrinsic ipRGC response. The long wavelength stimulus with
low melanopsin excitation (9.7 a-opic lux) was presented as
the control and to account for autonomic pupillary reactivity
and is not reported.
Statistical Analysis
Statistical analyses were performed using commercially avail-
able statistical software (IBM SPSS, version 21; IBM Corpora-
tion, Armonk, NY, USA). Normality was assessed using the
Shapiro-Wilk test. Independent sample t-tests evaluated each
variable (presence of IOL, initial constriction, PIPR, sleep
quality, sleep efficiency, and level of depression) between the
CNV and geographic atrophy patients, as well as between the
control group and AMD group. Spearman’s correlation
coefficient was used to determine the association between
the pupil metrics (initial constriction and PIPR) and sleep
(global score, sleep quality, and sleep efficiency), as well as
between the pupil metrics and depression scores within the
AMD group. These analyses were repeated after excluding the
five patients who were taking antidepressant medication. The
association between visual acuity and number of injections
administered with depression and sleep scores was determined
using correlation analysis. Where a significant correlation was
found, linear regression analyzed the relationship between
sleep and depression scores and the pupil metrics. Multiple
regression analysis was completed to account for the effect of
age, presence of IOL, and treatment frequency. A value of P <
0.05 was considered statistically significant.
RESULTS
There was no significant difference between CNV (n¼ 46) and
GA (n ¼ 7) patients for initial pupil constriction amplitude,
PIPR amplitude, depression score, and global sleep score.
Therefore, AMD patients with CNV and GA were combined
into a single group for additional analyses. There was no
significant effect of IOL surgery on all parameters. Multiple
regression analysis showed no effect of age (b¼ 0.14, P¼ 0.07,
R2¼ 0.05); IOL (b¼1.8, P¼ 0.13, R2¼ 0.03); and treatment
frequency (b ¼0.2, P ¼ 0. 16, R2 ¼ 0.08) on the PIPR. The
mean (6 standard deviation) values of all measured variables
(pupil parameters, sleep and mood scores) for the AMD group
and control group are given in Table 2. The long wavelength
stimulus showed a low variability (63.3%), indicative of a
minimal effect of autonomic reactivity. The pupil parameters
(pupil constriction and PIPR) for the AMD group were
significantly reduced compared to the control group, indicat-
ing lesser pupil constriction amplitudes at stimulus onset and
at post-illumination. The group with AMD had a higher global
sleep score indicating poorer sleep compared to controls.
Analysis of the sleep factor components demonstrated sleep
efficiency scores were higher in the AMD group. However; the
sleep quality score was not significantly different between
groups. The group with AMD had a significantly higher level of
depression compared to the control group (Table 2). All
participants scored less than 4 on the SPAQ index, with the
exception of one AMD patient who scored 8 out of a possible
24 and was still below the cutoff for seasonal affective disorder.
Correlation analyses identified a positive association between
the PIPR amplitude and global sleep score (r¼ 0.34, P ¼ 0.01)
for the AMD group (Fig. 1A). As the amplitude of PIPR
decreased, indicating a reduced sustained constriction, the
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global score increased, demonstrating poorer sleep behavior
(F1,51 ¼ 6.75, P ¼ 0.01, R2 ¼ 0.12). Correlations between the
PIPR amplitude and sleep efficiency and sleep quality factors in
the AMD group identified that poorer sleep efficiency was
associated with a decrease in PIPR amplitude (r¼0.36, P¼0.01;
regression, F1,51 ¼ 7.55, P ¼ 0.01, R2 ¼ 0.13; Fig. 1C), but no
correlation was found between sleep quality and PIPR (r¼ 0.17,
P ¼ 0.23; Fig. 1E). Initial pupil constriction amplitude did not
correlate with the global sleep score (r¼ 0.09, P¼ 0.52); sleep
efficiency (r ¼ 0.12, P ¼ 0.41); or sleep quality (r ¼ 0.05, P ¼
0.71) in the AMD group. Sleep scores (CNV and GA groups) did
not correlate with visual acuity (r¼0.04, P¼ 0.77) or number
of injections administered in the CNV group (r¼0.19, P¼0.19).
For the depression score analysis, 2/53 AMD patients met
the criteria for major depression, 2 of the 53 AMD patients had
possible major depression and 6 of the 53 AMD patients had
symptoms of subthreshold depression. Five AMD patients were
taking antidepressant medication; one control participant had
subthreshold depression symptoms while all other control
participants showed no clinical signs of depression. There was
no correlation between PIPR and depression score for the
AMD group (r¼ 0.23, P¼ 0.1; Fig. 2A). The patients with AMD
(n¼ 4) with major or possible major depression, according to
the CES-D scores, did not have significantly reduced PIPR
amplitudes compared to the mean PIPR for the AMD group.
Exclusion of the patients on antidepressant medication did not
affect the average pupil measurements. There was no
correlation between depression scores and the initial pupil
constriction amplitude (P > 0.05). Depression scores did not
correlate with visual acuity in the CNV/GA group (r¼0.03, P¼
0.85) or number of injections administered in the CNV group
(r¼ 0.13, P ¼ 0.38).
DISCUSSION
This is the first study to investigate the relationship between
ipRGC function, sleep behavior, and depression in AMD. We
hypothesized that altered ipRGC function in AMD will lead to
sleep and mood disturbances due to their projections to
corresponding brain areas. Based on previous studies,17,21 we
proposed that aberrant light signaling through dysfunctional
ipRGCs will contribute to these behavioral changes. A positive
correlation was observed between reduced ipRGC function as
measured by the melanopsin-mediated PIPR and poorer sleep
efficiency, with ipRGC dysfunction accounting for 13% of the
reduced sleep efficiency. There was no relationship between
ipRGC function and risk of depression in AMD patients;
however, a limitation of this study is that the number of
depressed AMD patients was low, hence further studies with a
larger cohort are needed.
All three photoreceptor types; rods, cones, and ipRGCs are
affected in advanced AMD5,55 and contribute to the initial pupil
constriction during stimulus presentation,47 whereas ipRGCs
and rods contribute to the sustained post-illumination pupil
response.12,15 At least five different ipRGC subtypes (M1–
M5)
56,57 project to nonimage forming centers in the rodent
brain, with the M1 and M2 subtypes likely to be homologous to
the outer and inner stratifying melanopsin cells found in
humans and nonhuman primates.58–60 A recent mouse study
using single M1 ipRGC axonal tracing and confocal microscop-
ic analysis identified up to five different brain targets that
received input from a single M1 subtype ipRGC, indicating that
a single ipRGC can affect brain areas involved in numerous
light-mediated behaviors.61 Therefore, the correlation between
poor sleep efficiency and reduced PIPR may be attributed to
individual dysfunctional M1 ipRGCs projecting to both the SCN
and OPN.
Poor sleep is a common complaint in the aged population,62
but there is no evidence for a significant age-related difference
in sleep behavior,63,64 consistent with data from our healthy
control group, suggesting that the sleep problems detected in
TABLE 2. Mean (6 SD) Values for the Pupil Parameters, Sleep Component, and Depression Scores for AMD Patients and Healthy Control
Participants
Metrics
AMD Participants,
n ¼ 53
Control Participants,
n ¼ 20 P Value
Initial constriction amplitude (% baseline) 65.7 6 8.0 61.5 6 6.9 0.039*
PIPR amplitude (% baseline) 91.2 6 5.9 87.4 6 4.0 0.003*
PSQI global Score 6.5 6 3.2 4.5 6 2.5 0.013*
Sleep quality score 2.6 6 1.7 1.9 6 1.2 0.057
Sleep efficiency score 1.5 6 1.1 0.8 6 0.5 0.001*
CES-D score 9.3 6 9.1 2.9 6 4.0 < 0.001*
* P < 0.05.
FIGURE 1. Correlation between PIPR and sleep components. The
scatterplot and linear regression lines show the association between
the PIPR to a blue light stimulus (kmax ¼ 448 nm) and sleep
components in AMD patients (n ¼ 53; A, C, E) and healthy control
participants (n ¼ 20; B, D, F). The horizontal line in the top graphs
indicates a cutoff point in the global score to distinguish between
‘‘good’’ and ‘‘poor’’ sleep.
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the AMD group are secondary to comorbidities rather than to
aging.64 Furthermore, ipRGC function is robust to aging,42,65
with one study showing an enhanced response to high
irradiance short wavelength light associated with advancing
age.66 Therefore, it is unlikely that the advanced age of the
participants provided the basis for the association between
ipRGC dysfunction and poor sleep efficiency in this study.
Other contributors to poor sleep behavior in the elderly may
include changes relating to time in REM and slow-wave sleep,67
medical or psychiatric illness,64 and sleep-related disorders
such as restless legs syndrome or sleep apnea,68,69 although
only sleep apnea has been previously associated with AMD.69
The sleep quality component of the PSQI questionnaire
considers these contributing factors as it addresses sleep
disturbances and perceived sleep quality; however, these were
nonsignificant in our cohort.
Depression in AMD has been attributed to functional
disabilities and loss of independence due to impaired
vision.24–26,70,71 Of the AMD patients in this study, 28% had
either met criteria for risk of depression or were taking
antidepressant medication. However, no correlation between
ipRGC function and depression in advanced AMD was found,
hence our hypothesis for a causal relationship between the
dysfunction of these cells and altered signaling to mood
centers could not be evaluated in this sample. Irregular light
exposure can influence cognitive and mood functions directly
through ipRGCs21 as demonstrated in patients with SAD who
have a reduced PIPR amplitude.22 Seasonal affective disorder
may be caused by an abnormal response to seasonal light
changes,72 with melanopsin gene variants increasing the risk
for SAD in 5% of individuals.73 As the SAD patients had no
ocular pathology, the lower PIPR amplitude may be due to
irregular light exposure, although this was not measured in
that study.22 Our AMD cohort did not report any symptoms of
SAD; therefore, the reduced PIPR amplitude in our study may
be due to pathologic ipRGC dysfunction that leads to aberrant
inputs to the brain, rather than due to irregular light exposure.
It is still unknown which ipRGC subtype(s) project to mood
centers in the human brain and whether these projections are
affected by AMD. Visual acuity and number of intravitreal
injections did not correlate with the depression scores in this
study. Visual impairment is a risk factor for depression, but it is
not an inevitable consequence of vision loss and depression
can occur regardless of the level of vision impairment.24,74
Further research is needed to determine the cause of the
association between AMD and depression.
In conclusion, this study provides the first evidence that
ipRGC dysfunction contributes to reduced sleep efficiency in
patients with advanced AMD. With subtypes of melanopsin
ipRGCs that stratify in different regions of the inner plexiform
layer and project differentially to the SCN and OPN, this new
knowledge advances insights into ipRGC contributions to AMD
and its nonvision-related disorders, allowing a further under-
standing of this complex condition.
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